Artesunate attenuates ACLT-induced osteoarthritis by suppressing osteoclastogenesis and aberrant angiogenesis
Authors:
- 1 December 2017
- journal article
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 96, 410-416
Abstract
No abstract availableKeywords
This publication has 40 references indexed in Scilit:
- Objectively Measured Physical Activity and Symptoms Change in Knee OsteoarthritisThe American Journal of Medicine, 2016
- Intra-articular treatment of knee osteoarthritis: from anti-inflammatories to products of regenerative medicineThe Physician and Sportsmedicine, 2016
- Elevated marrow inflammatory cells and osteoclasts in subchondral osteosclerosis in human knee osteoarthritisJournal of Orthopaedic Research, 2015
- OsteoarthritisThe Lancet, 2015
- Inhibited osteoclastic bone resorption through alendronate treatment in rats reduces severe osteoarthritis progressionBone, 2014
- Novel artemisinin derivatives with potential usefulness against liver/colon cancer and viral hepatitisBioorganic & Medicinal Chemistry, 2013
- Clinical comorbidities, treatment patterns, and direct medical costs of patients with osteoarthritis in usual care: a retrospective claims database analysisJournal of Medical Economics, 2011
- From osteoarthritis treatments to future regenerative therapies for cartilageDrug Discovery Today, 2009
- Molecular Modes of Action of Artesunate in Tumor Cell LinesMolecular Pharmacology, 2003
- Qinghaosu (Artemisinin): an Antimalarial Drug from ChinaScience, 1985